Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2011 Dec 15;17(24):7505-7.
doi: 10.1158/1078-0432.CCR-11-2372.

Differential role of BCL2 in molecular subtypes of diffuse large B-cell lymphoma

Kieron Dunleavy  1 , Wyndham H Wilson
Affiliations
Comment

Differential role of BCL2 in molecular subtypes of diffuse large B-cell lymphoma

Kieron Dunleavy et al. Clin Cancer Res. .

Abstract

Gene expression profiling has been used to divide diffuse large B-cell lymphoma into distinct molecular subtypes with different outcomes following immunochemotherapy. Recently, researchers have shown much interest in investigating the role of biomarkers, such as BCL2, in predicting outcome in diffuse large B-cell lymphoma, particularly in the context of these molecular subtypes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Shown here are potential mechanisms of BCL-2 mRNA expression in a series of unselected cases of germinal center B-like (GCB) and activated B-like (ABC) DLBCL. The array shows that most BCL-2 expression in GCB DLBCL is associated with t(14:18), although a subset of BCL-2 expressing cases do not harbor this translocation and other mechanisms of activation are at play. In ABC DLBCL, while activation of NF kappa B is associated with BCL-2 over-expression, it is likely that other mechanisms of activation are also important.
See this image and copyright information in PMC

Comment on

References

    1. Iqbal J, Meyer PN, Smith L, Johnson NA, Vose JM, Greiner TC, et al. BCL2 Predicts Survival in Germinal Center B-cell-like Diffuse Large B-Cell Lymphoma Treated with CHOP-like therapy and Rituximab. Clin Cancer Res. 2011 Sep 20; - PMC - PubMed
    1. Tsujimoto Y, Gorham J, Cossman J, Jaffe E, Croce CM. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science. 1985 Sep 27;229(4720):1390–3. - PubMed
    1. Gascoyne RD, Adomat SA, Krajewski S, Krajewska M, Horsman DE, Tolcher AW, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin’s lymphoma. Blood. 1997 Jul 1;90(1):244–51. - PubMed
    1. Brien G, Trescol-Biemont MC, Bonnefoy-Berard N. Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis. Oncogene. 2007 Aug 23;26(39):5828–32. - PubMed
    1. Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002 Apr 15;99(8):2685–93. - PubMed

MeSH terms

Substances